i
Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022
-
7 08 2022
-
-
Source: MMWR Morb Mortal Wkly Rep. 71(27):878-884
[PDF-147.56 KB]
Details:
-
Alternative Title:MMWR Morb Mortal Wkly Rep
-
Personal Author:
-
Corporate Authors:
-
Description:Immunocompromised persons are at increased risk for severe COVID-19-related outcomes, including intensive care unit (ICU) admission and death (1). Data on adults aged ≥18 years hospitalized with laboratory-confirmed COVID-19 from 10 U.S. states in the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to assess associations between immunocompromise and ICU admission and in-hospital death during March 1, 2020-February 28, 2022. Associations of COVID-19 vaccination status with ICU admission and in-hospital death were also examined during March 1, 2021-February 28, 2022. During March 1, 2020-February 28, 2022, among a sample of 22,345 adults hospitalized for COVID-19, 12.2% were immunocompromised. Among unvaccinated patients, those with immunocompromise had higher odds of ICU admission (adjusted odds ratio [aOR] = 1.26; 95% CI = 1.08-1.49) and in-hospital death (aOR = 1.34; 95% CI = 1.05-1.70) than did nonimmunocompromised patients. Among vaccinated patients,* those with immunocompromise had higher odds of ICU admission (aOR = 1.40; 95% CI = 1.01-1.92) and in-hospital death (aOR = 1.87; 95% CI = 1.28-2.75) than did nonimmunocompromised patients. During March 1, 2021-February 28, 2022, among nonimmunocompromised patients, patients who were vaccinated had lower odds of death (aOR = 0.58; 95% CI = 0.39-0.86) than did unvaccinated patients; among immunocompromised patients, odds of death between vaccinated and unvaccinated patients did not differ. Immunocompromised persons need additional protection from COVID-19 and using multiple known COVID-19 prevention strategies,| including nonpharmaceutical interventions, up-to-date vaccination of immunocompromised persons and their close contacts,| early testing, and COVID-19 prophylactic (Evusheld) and early antiviral treatment,| can help prevent hospitalization and subsequent severe COVID-19 outcomes among immunocompromised persons.
-
Subjects:
-
Source:
-
Pubmed ID:35797216
-
Pubmed Central ID:PMC9290380
-
Document Type:
-
Name as Subject:
-
Volume:71
-
Issue:27
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
